ABL Diagnostics S.A Press Releases - EIN Presswire - Press Release Distribution Service

Published on July 31, 2026 - 06:00 GMT

ABL Diagnostics Announces CE-IVD of DeepChek® Whole Genome HIV-1 Genotyping v1.2

The first and only CE-IVD whole genome HIV assay, with 500 copies/mL sensitivity for comprehensive drug resistance testing WOIPPY, FRANCE, July 31, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – Compartiment B – ISIN: FR001400AHX6), a …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 28, 2026 - 06:00 GMT

ABL Diagnostics Announces Availability of UltraGene Viral Meningitis Following CE-IVD Registration by ABL SA Luxembourg

WOIPPY, FRANCE, July 28, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – Compartiment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions for infectious diseases, announces the commercial availability of …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 27, 2026 - 06:00 GMT

ABL Diagnostics Announces UltraGene Respiratory Pathogens 21 After CE-IVD Registration by ABL SA Luxembourg

WOIPPY, FRANCE, July 27, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – Compartiment B – ISIN : FR001400AHX6), a company specialized in molecular diagnostic solutions for infectious diseases, announces the commercial availability of …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 22, 2026 - 16:00 GMT

ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations

Strengthening Life Sciences and Infectious Diseases Activities at Genopole, with Synergies in Virology, Biosafety, and Biological Control WOIPPY, FRANCE, July 22, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – Compartment B – ISIN: …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 22, 2026 - 16:00 GMT

ABL Diagnostics désignée par le Tribunal de commerce d'Évry pour la reprise des activités de TEXCELL

Renforcement en sciences de la vie et maladies infectieuses au Genopole, avec synergies en virologie, biosécurité et contrôle biologique. WOIPPY, FRANCE, July 22, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – Compartiment B – ISIN : …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 17, 2026 - 16:00 GMT

ABL Diagnostics Expands Its Tuberculosis NGS Portfolio to Targeted and Whole Genome Sequencing

Completing ABL Diagnostics' infectious disease portfolio by extending its proven DeepChek® and UltraGene expertise to comprehensive tuberculosis genomics WOIPPY, FRANCE, July 17, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 16, 2026 - 16:00 GMT

ABL Diagnostics Confirms BSI Partnership for IVDR Transition and Long-Term Availability of its CE-IVD Medical Devices

Expanded GRC and R&D capabilities plus an enhanced QMS accelerate IVDR-compliant innovation and prepare for FDA QMSR and global markets. WOIPPY, FRANCE, July 16, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris – ISIN: FR001400AHX6 – …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 15, 2026 - 16:00 GMT

ABL Diagnostics accélère sa stratégie de santé numérique avec l'achèvement d'un premier jalon majeur de MyNadis

Dix ans après l'acquisition de Fedialis Medica, ABL Diagnostics progresse dans le développement de son système numérique pour le suivi des parcours de soins WOIPPY, FRANCE, July 15, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (Euronext Paris : ABLD) …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 15, 2026 - 06:00 GMT

ABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral Resistance

Reinforcing long-term IP strength in molecular diagnostics and supporting global laboratory partners WOIPPY, FRANCE, June 15, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a specialist in molecular diagnostics, bioinformatics and …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 10, 2026 - 06:00 GMT

ABL Diagnostics Showcases Scientific Progress at EMHH 2026, Supporting Strategic Positioning in Molecular Technologies

WOIPPY, FRANCE, June 10, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a specialist in molecular technologies, bioinformatics and decision-support solutions for infectious diseases, announces the presentation of three scientific …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 9, 2026 - 06:00 GMT

ABL Diagnostics Advances Platform-Agnostic NGS Strategy Through DeepChek® Verification on Element Biosciences’ AVITI™

Ongoing verification study supports compatibility of DeepChek® with the AVITI™ platform. Expands opportunities in infectious disease sequencing workflows. WOIPPY, FRANCE, June 9, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 8, 2026 - 06:00 GMT

ABL Diagnostics Deepens Laboratory Footprint with Launch of HybridChek for HIV and Tuberculosis Whole Genome Sequencing

By Offering Amplicon and Hybrid Capture on a Single Bioinformatics platform, the Company Expands Capabilities to Cover All Pathogen Sequencing Needs. WOIPPY, FRANCE, June 8, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 1, 2026 - 06:00 GMT

ABL Diagnostics Broadens UltraGene Syndromic qPCR Portfolio

A 45-reference UltraGene range, new respiratory panels and high-multiplex prototypes strengthen ABL Diagnostics molecular testing platform. ABL Diagnostics SA (EPA:ABLD) WOIPPY, MOSELLE, FRANCE, June 1, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics ( …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 28, 2026 - 16:00 GMT

UltraGene Ebola: Multiplex qPCR for Outbreak Preparedness

A multiplex qPCR assay designed for Bundibugyo coverage, Ebola species differentiation, validation readiness and regulatory preparedness. ABL Diagnostics SA (EPA:ABLD) WOIPPY, MOSELLE, FRANCE, May 28, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics ( …

Distribution channels: Business & Economy, Companies ...

Published on May 28, 2026 - 06:00 GMT

ABL Diagnostics Advances NGS for CMV Resistance Monitoring at SEIMC 2026

DeepChek® NGS ecosystem maps viral resistance mutations to next-generation therapies, unlocking new insights for monitoring immunocompromised patient cohorts. WOIPPY, FRANCE, May 28, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on May 27, 2026 - 16:00 GMT

ABL Diagnostics Secures New Global Tenders and Continues to Expand Distribution Network

ABL Diagnostics accelerates international growth with key public contracts and platform-agnostic microbiology solutions across EMEA, Asia, and the US. WOIPPY, FRANCE, May 27, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a leading …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on May 26, 2026 - 06:00 GMT

ABL Diagnostics et le CHRU Nancy : premier bilan positif pour le projet PREDAVIR après 6 mois

WOIPPY, FRANCE, May 26, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”) et le CHRU Nancy annoncent le succès des six premiers mois du projet PREDAVIR (PREvenir le DAnger VIRal), soutenu par le FEDER Grand Est. Les avancées …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on May 21, 2026 - 06:00 GMT

ABL Diagnostics Drives EMEA Expansion with VELA Diagnostics Partnership

Leveraging an annualized run-rate baseline of ~1M€ from late 2025, the Company accelerates its strategic rollout of automated CE-IVD HIV testing solutions. ABL Diagnostics SA (EPA:ABLD) WOIPPY, MOSELLE, FRANCE, May 21, 2026 /⁨EINPresswire.com⁩/ -- ABL …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on May 20, 2026 - 06:00 GMT

ABL Diagnostics Unveils Next-Generation HIV Genotyping Innovation with the Industry’s Broadest Portfolio

International HIV publication further validates the DeepChek® brand for HIV genotyping and long- & short-read NGS, reinforcing ABL’s leadership in HIV genomics. WOIPPY, FRANCE, May 20, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on May 20, 2026 - 06:00 GMT

ABL Diagnostics renforce son leadership mondial dans le génotypage VIH avec DeepChek® Whole Genome HIV

Une nouvelle publication valide la technologie DeepChek® et confirme la position de leader d’ABL Diagnostics dans le génotypage VIH et les solutions NGS WOIPPY, FRANCE, May 20, 2026 /⁨EINPresswire.com⁩/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...